Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
Date:11/14/2013

, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients. 

About Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide. Approximately 60 percent of GBM patients treated with temozolomide experience tumor progression within one year. More than half of glioblastoma patients will fail the currently approved therapies.

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For more information, please visit www.delmarpharma.com or follow us on Twitter @delmarpharma or Facebook.com/delmarpharma.

Safe Harbor Statement
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Lupin , Strides ... MPP Sub-licensees to Fourteen Companies     ... expansion of its network of generic manufacturers to 14 companies ... antiretrovirals (ARVs). New companies Lupin and Strides Arcolab recently signed ... the MPP licensed from ViiV Healthcare two months after its ...
(Date:7/1/2015)... , July 1, 2015  Celsion Corporation (NASDAQ: ... announced that Michael H. Tardugno , Chairman, President ... Fitzgerald,s Inaugural Healthcare Conference on Wednesday, July 8, 2015, ... at Le Parker Meridien Hotel located at 119 W. ... 10019. A copy of the presentation will ...
(Date:7/1/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... and chief executive officer, is scheduled to present ... an update on Egalet,s marketed product SPRIX ... product OXAYDO ™ (oxycodone HCI, USP) tablets ...
Breaking Medicine Technology:The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3
... June 1, 2011 Reportlinker.com ... research report is available in ... Interventional Neurology - Global ... Market Forecasts to 2017 ...
... 2011 Repro-Med Systems, Inc., (REPR.PK) announced today that ... Administration (FDA) to begin U.S. marketing of its new ... the HIgh Flo™ RMS Subcutaneous Needle Sets.  The needle ... subcutaneous tissue.  The needle sets have previously been approved ...
Cached Medicine Technology:Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12FDA Approves Marketing of RMS Subcutaneous Needle Sets 2FDA Approves Marketing of RMS Subcutaneous Needle Sets 3
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will team ... America (HCA), as it further expands its Strategic Alliance Partnership Program for raising ... new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon to ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted ... 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event ... petting zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... author Lisa Stolzenberg, a Professor in FIU’s School of International and Public Affairs. ... 17 years who participated in the National Survey on Drug Use and Health, ...
(Date:7/1/2015)... ... 2015 , ... Element Blue ™, a leading IT ... has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is used ... sources providing an environment where users can view and compare real-time and historic ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the newest and ... two or more Bunion Booties directly from their website, http://www.BunionBootie.com can ... misaligned toes and its ultra thin properties allow for protection against rubbing footwear ...
Breaking Medicine News(10 mins):Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
... Researchers from MetroHealth Medical Center and Case Western Reserve ... who have had previous spontaneous preterm births with 17 ... another preterm birth would consequently reduce both short-term and ... year. The results of their study are reported in ...
... medication labels in languages other than English, few New ... limited-English patients face serious risk of medication error, according ... Medicine presented today at the annual meeting of the ... ,"Imagine, as an English speaker, picking up ...
... out of three sexually active older adults infected with HIV ... researchers//. A survey of 260 HIV-positive older adults found that ... were in a relationship. ,AIDs cases among the ... for Disease Control and Prevention, they will account for half ...
... the potential for medication errors, says a new study by ... May issue of the journal Medical Care. ,The ... College of Pharmacy professor Daniel C. Malone, Ph.D., who is ... Research on Therapeutics at the Critical Path Institute. ...
... for their antiretroviral medications experienced interruptions in drug ... logistical disruptions. These treatment interruptions led to the ... ,These findings by a team led ... Makerere University, Kampala, and UCSF are reported in ...
... of global warming keeps coming up from across the world. ... seawaters are killing marine life in their thousands. ... ago it was reported that a Norwegian glacier had shrunk ... a usually frozen fjord (a long narrow arm of ...
Cached Medicine News:Health News:Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs 2Health News:Many NYC Pharmacies Fail to Translate Prescription Labels for Patients Who Don't Understand English 2Health News:Many NYC Pharmacies Fail to Translate Prescription Labels for Patients Who Don't Understand English 3Health News:One-Third of Sexually Active Older Adults With HIV/AIDs Has Unprotected Sex 2Health News:Pharmacists' Workload Contributes To Errors 2Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 3
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... offers easy operation, maintenance, and training. Whether you ... to the powerful VITROS 5,1 FS, the VITROS ... right the first time. Its that simple. , ... and easy-to-use. The VITROS 350 comes complete with ...
Meet Galileo, the best reason to move to automation; the best way to upgrade your capabilities....
Medicine Products: